Cellular Immune Response after Vaccination in Patients with Cancer—Review on Past and Present Experiences DOI Creative Commons

Maria Madeleine Rüthrich,

Nicola Giesen, Sibylle C. Mellinghoff

и другие.

Vaccines, Год журнала: 2022, Номер 10(2), С. 182 - 182

Опубликована: Янв. 25, 2022

Patients with cancer are at particular risk for infection but also have diminished vaccine responses, usually quantified by the level of specific antibodies. Nonetheless, vaccines specifically recommended in this vulnerable patient group. Here, we discuss cellular part response patients cancer. We summarize experience prior to and during SARS-CoV-2 pandemic different subgroups, why, especially cancer, T cells may be more reliable correlate protection. Finally, provide a brief outlook on options improve vaccines.

Язык: Английский

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact DOI Open Access
Marc Lipsitch, Florian Krammer, Gili Regev‐Yochay

и другие.

Nature reviews. Immunology, Год журнала: 2021, Номер 22(1), С. 57 - 65

Опубликована: Дек. 7, 2021

Язык: Английский

Процитировано

313

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety DOI Open Access
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel

и другие.

Nature Reviews Clinical Oncology, Год журнала: 2022, Номер 19(6), С. 385 - 401

Опубликована: Март 11, 2022

Язык: Английский

Процитировано

179

Adaptive Immune Responses and Immunity to SARS-CoV-2 DOI Creative Commons
Dragan Primorac,

Kristijan Vrdoljak,

Petar Brlek

и другие.

Frontiers in Immunology, Год журнала: 2022, Номер 13

Опубликована: Май 4, 2022

Since the onset of COVID-19 pandemic, medical field has been forced to apply basic knowledge immunology with most up-to-date SARS-CoV-2 findings and translate it population whole world in record time. Following infection viral antigen, adaptive immune responses are activated mainly by particle encounters antigen-presenting cells or B cell receptors, which induce further biological interactions defend host against virus. After warded off, immunological memory is developed. The SARS-CoV cellular immunity shown persist even 17 years after infection, despite undetectable humoral component. Similar demonstrated for T a shorter period assessing interferon-gamma levels when heparinized blood stimulated virus-specific peptides. also play an irreplaceable part reaction as backbone response. They both provide signals activation maturation, competence, production IgA was be significant influence mediating mucosal first defense mechanism development nasal vaccines. Here, we interpret recent available research, encompasses significance current understanding activity, compare among naive, exposed, vaccinated donors. Our data showed that those who recovered from EMA-approved vaccines had long-lasting immunity. Additionally, analyze immunocompromised patients mediated impact clonality pandemic regarding breakthrough infections variants concern, B.1.617.2 (Delta) B.1.1.529 (Omicron) variants.

Язык: Английский

Процитировано

99

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel DOI Creative Commons
Noopur Raje, Kenneth C. Anderson, Hermann Einsele

и другие.

Blood Cancer Journal, Год журнала: 2023, Номер 13(1)

Опубликована: Авг. 1, 2023

Abstract Bispecific antibodies (BsAbs) are emerging as an important novel class of immunotherapeutic agents for the treatment multiple myeloma (MM), and set to be more widely used in clinical practice. However, this new therapies is associated with a distinct adverse event (AE) profile that includes cytokine release syndrome immune effector cell-associated neurotoxicity syndrome, well AEs leading increased infection risk such cytopenias hypogammaglobulinemia, infections themselves. As preliminary data shows compared conventional MM regimens, immunomodulatory drugs, proteasome inhibitors, anti-CD38 monoclonal (mAbs), guidance on monitoring, prophylaxis required. This review provides consensus recommendations from panel 13 global experts, following meeting August 2022. The objective was existing literature identify relevant information all BsAbs patients MM, discuss experience experts managing these infections. outlined here can guide management factors, hypogammaglobulinemia neutropenia. In addition, they prophylaxis, bacterial, viral fungal infections, including interest, coronavirus 2019 (COVID-19), use vaccinations prior during BsAb treatment. have been graded by based level available. Key include universal herpes simplex varicella zoster virus screening hepatitis B reactivation patients, monthly intravenous immunoglobulin immunoparesis absence life-threatening infectious manifestations, colony-stimulating factors Grade 3 neutropenia, pneumocystis jirovecii pneumonia no routine anti-fungal prophylaxis.

Язык: Английский

Процитировано

87

IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies DOI
Guido Lancman, Kian Parsa, Krzysztof Kotlarz

и другие.

Blood Cancer Discovery, Год журнала: 2023, Номер 4(6), С. 440 - 451

Опубликована: Сен. 28, 2023

Abstract BCMA-targeted bispecific antibodies (BiAb) are efficacious in relapsed/refractory multiple myeloma; however, serious infections have emerged as important toxicities. In this retrospective study, we characterized all and their risk factors, evaluated the impact of infection prophylaxis patients treated with BiAbs. Among 37 patients, 15 (41%) experienced a grade 3–5 infection, two infection-related deaths during deep remissions. Most (84%) occurred disease The cumulative probability increased over time no plateau. responders (n = 26), profound hypogammaglobulinemia 100% continued throughout entire duration treatment. During periods when were receiving intravenous immunoglobulin (IVIg), rate was 90% lower than observation (incidence ratio, 0.10; 95% confidence interval, 0.01–0.80; P 0.0307). No other factors for identified. This study demonstrates that is universal BiAbs, potentially abrogating most risk. Significance: To best our knowledge, first to comprehensively analyze mitigation strategies prevent myeloma anti-BCMA antibodies. Profound prolonged among responders, while replacement associated rates infections. See related commentary by Garfall Stadtmauer, p. 427 . article featured Selected Articles from Issue, 419

Язык: Английский

Процитировано

57

The role of vaccines in the COVID-19 pandemic: what have we learned? DOI Creative Commons
Florian Krammer

Seminars in Immunopathology, Год журнала: 2023, Номер 45(4-6), С. 451 - 468

Опубликована: Июль 12, 2023

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged late in 2019 and caused the disease (COVID-19) pandemic that has so far claimed approximately 20 million lives. Vaccines were developed quickly, became available end of 2020, had a tremendous impact on protection from SARS-CoV-2 mortality but with emerging variants morbidity was diminished. Here I review what we learned COVID-19 vaccinologist's perspective.

Язык: Английский

Процитировано

43

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN) DOI Open Access
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt

и другие.

Leukemia, Год журнала: 2023, Номер 37(6), С. 1175 - 1185

Опубликована: Май 4, 2023

Язык: Английский

Процитировано

33

Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR DOI Open Access
Megan Schwarz, Denis Torre, Daniel Lozano‐Ojalvo

и другие.

Nature Biotechnology, Год журнала: 2022, Номер 40(11), С. 1680 - 1689

Опубликована: Июнь 13, 2022

Язык: Английский

Процитировано

38

Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients DOI Creative Commons
Adolfo Aleman, Oliver Van Oekelen,

Bhaskar Upadhyaya

и другие.

Cancer Cell, Год журнала: 2022, Номер 40(5), С. 441 - 443

Опубликована: Апрель 6, 2022

Язык: Английский

Процитировано

35

Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review DOI Creative Commons
Vanessa Piechotta, Sibylle C. Mellinghoff, Caroline Hirsch

и другие.

Blood Cancer Journal, Год журнала: 2022, Номер 12(5)

Опубликована: Май 31, 2022

The efficacy of SARS-CoV-2 vaccination in patients with hematological malignancies (HM) appears limited due to disease and treatment-associated immune impairment. We conducted a systematic review prospective studies published from 10/12/2021 onwards medical databases assess clinical parameters, humoral cellular immunogenicity adverse events (AE) following two doses COVID-19 approved vaccines. In 57 eligible reporting 7393 patients, outcomes were rarely reported rates infection (range 0-11.9%), symptomatic (0-2.7%), hospital admission (0-2.8%), or death (0-0.5%) low. Seroconversion ranged 38.1-99.1% across the highest response rate myeloproliferative diseases lowest chronic lymphocytic leukemia. Patients B-cell depleting treatment had lower seroconversion as compared other targeted treatments chemotherapy. vaccine-induced T-cell was heterogeneously (26.5-85.9%). Similarly, AEs (0-50.9% ≥1 AE, 0-7.5% serious AE). conclusion, HM present impaired specific patterns. light ongoing pandemic easing mitigation strategies, new approaches avert severe are urgently needed for this vulnerable patient population that responds poorly current vaccine regimens.

Язык: Английский

Процитировано

35